UNSPSC 51271605: Capsaicin

This classification denotes a nonnarcotic analgesic and capsaicinoid with the molecular formula C18H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S07O44R1ZM, chemically known as nonanamide, n-vanillyl- (8ci) but generally known as capsaicin, which bears US NIH Compound Identifier 2998. European Medicines Agency schedules Capsaicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13229MIG. World Health Organization schedules capsaicin in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, CAPSAICIN remains the US FDA Preferred Term for this commodity. Capsaicin bears US NLM identifiers UMLS ID C0006931 and NCI Concept Code C339. SMILES: O=C(NCC1CC(OC)C(O)CC1)CCCCCCCC.

UNSPSC 51271605 Capsaicin, a Commodity code, shows limited recent state and local procurement activity that aligns with the code's nominal scope. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. However, the solicitation does not identify capsaicin as a named or priority product line; instead, it requests comprehensive pricing for an unspecified roster of pharmaceutical products with designated National Drug Codes (NDCs), submitted through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and demonstrate pricing flexibility through flat price, net price, or WAC-minus structures.

The RFP represents a cooperative purchasing vehicle spanning multistate participation, with proposals due March 26, 2026, and evaluation weighted heavily toward price competitiveness (75 percent), with secondary weight on fixed pricing, EDI capability, administrative fee compliance, and data format requirements. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, and member-specific needs. Awarded vendors will be provided to authorized wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026 and a two-year contract term for new responders, optional extensions at MMCAP discretion, and incumbent amendment alignment through June 30, 2028. Vendors must maintain comprehensive insurance coverage including $5 million per-occurrence commercial general liability, $2 million network security and privacy liability, and $2 million professional liability, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Specific budget figures or award values are not disclosed.